Supporting Startups
Sparking Connections for More Durable Companies
In 2025, LabCentral supported founders in building breakthrough science, as well as honing the skills, confidence, and connections required to turn that science into durable companies. Through curated introductions, hands-on gatherings, and deep partnership engagement, startups gained access to industry perspective and relationships at critical inflection points—while partners and sponsors engaged with the emerging science and entrepreneurial talent, shaping what comes next.
Golden Tickets
Golden Tickets empower sponsors to directly support early-stage biotech startups by underwriting the cost of residency at LabCentral’s 700 Main Street facility. Each Golden Ticket provides $50,000 in lab space, along with access to shared equipment, infrastructure, and community.
For startups, Golden Tickets reduce early financial friction and enable teams to move faster. For sponsors, the program creates early, meaningful engagement with founders—grounded in shared progress rather than transactional access.
2025 Golden Ticket Highlights
LabCentral Ignite Golden Tickets provide founders with an immersive experience that combines lab access with mentorship and network support. Selected through a holistic review process, Ignite Golden Tickets support entrepreneurs who may otherwise face barriers in launching and scaling a biotech company.
Founder Momentum Beyond the Program
Ignite Golden Ticket alumni continued to build meaningful traction in 2025, raising a combined $19.73 million across financing rounds and non-dilutive funding. Together, these outcomes reflect LabCentral’s long-term impact: equipping founders with the confidence, credibility, and connections to sustain progress well beyond a single program year.
- Cellens — $6.5M Seed to advance its AI- and mechanobiology-driven bladder cancer diagnostic platform
- NeuroBionics — $10M oversubscribed Seed to accelerate first-in-human studies for its endovascular neuromodulation platform
- Venova Technologies — $2.23M NIH SBIR Phase II award to advance a novel, hormone-free contraceptive device
- Violet Therapeutics — $1M Part the Cloud grant supporting development of novel Alzheimer’s disease therapeutics
Investor & Partner Gatherings
Across Boston Biotech Investor Day, MALSI Day, and Luminescence, LabCentral hosted founders, investors, and partners in forums designed for candid exchange, expanded visibility, and relationship-building—creating environments where insight flowed in both directions and readiness accelerated.
Boston Biotech Investor Day (BBID)
The second annual BBID brought together 100+ investors and pharma partners alongside 48 early-stage companies developing transformative human health technologies. The invitation-only event was hosted with BioLabs, The Engine, and the Termeer Institute.
The program featured a keynote from Paula Soteropoulos, Chairman of the Board at Ensoma, on unlocking value through purposeful partnership, alongside a Silicon Valley Bank State of the Market and Investor Outlook led by Senior Vice President Mike Ritter. A candid panel discussion on negotiating from both sides of the table further explored how founders and investors assess risk, prioritize terms, and build alignment in today’s financing environment.
Massachusetts Life Sciences Innovation Day
The 18th annual Massachusetts Life Sciences Innovation (MALSI) Day brought together founders, scientists, investors, and industry leaders for the Commonwealth’s largest life sciences innovation showcase. Co-hosted with BioLabs, The Engine, and MassVentures, the event created a hands-on environment for discovery, dialogue, and early conviction.
The event included 24 university spinouts pitching to investors. Panel discussions focused on early-stage funding dynamics and navigating uncertainty in today’s capital environment, offering founders timely insight from leaders across science and business.
Luminescence: Rise & Fund
Held alongside BIO 2025, Luminescence: Rise & Fund kicked off the conference with a caffeine-charged morning showcase featuring a digital poster platform, strong coffee, and bold science. Resident companies shared their research and business strategies while investors and partners engaged in real-time conversations, just steps from the Boston Convention & Exhibition Center.
BrilliantStrings Therapeutics earned the $200K Lightning Pass, a larger-scale version of the Golden Ticket designed to accelerate early progress with greater non-dilutive support. InnDura Therapeutics received a CKD Golden Ticket, and VISKA.Bio won an audience-driven award through an interactive voting process, creating tangible momentum at a pivotal fundraising moment.
Follow LabCentral on LinkedIn to stay up to date on company milestones, partnerships, press releases, and community news.